Blog

Karen Knudsen: Looking forward to visiting Lombardi Comprehensive Cancer Center

Karen Knudsen/LinkedIn

Jan 8, 2025, 15:30

Karen Knudsen: Looking forward to visiting Lombardi Comprehensive Cancer Center

Karen Knudsen, Executive Strategic Advisor and Immediate Past CEO of ACS, shared a post on LinkedIn:

“Can’t wait for Thursday! I am very much looking forward to visiting colleagues later this week at Georgetown University, Lombardi Comprehensive Cancer Center and honored to deliver the Edward M. Kovach Cura Personalis Endowed Lecture.

This distinguished lecture series reflects a core value at Georgetown: cura personalis, or care for the whole person – a key component of cancer survivorship – encompassing not only medical outcomes but also the emotional, social, and psychological dimensions of recovery.

Survivors face unique challenges, and addressing these holistically is key to improving quality of life and fostering resilience.

Following the lecture, I am privileged to join a panel discussion featuring exceptional individuals dedicated to advancing cancer care:

Nicole Faison, CSM, a brilliant patient advocate
Dr. Louis M. Weiner, MD Director of Georgetown Lombardi Comprehensive Cancer Center, renowned for his leadership in cancer research and treatment.
Dr. Nina Kadan-Lottick, Director of the Survivorship Research Initiative at Georgetown Lombardi

I look forward to contributing to the dialogue and learning from the innovative work being done at Lombardi Cancer Center. Together, we can continue to drive progress for cancer survivors and their families.”

Karen Knudsen: Looking forward to visiting Lombardi Comprehensive Cancer Center

More posts featuring Karen Knudsen.

Karen E. Knudsen is the Executive Strategic Advisor and Immediate Past CEO of the American Cancer Society (ACS). Prior to joining ACS, Dr. Knudsen served as executive vice president of Oncology Services and enterprise director for Sidney Kimmel Cancer Center at Jefferson Health.

She also served as president for the Association of American Cancer Institutes (AACI) and on the board of directors of the American Association for Cancer Research (AACR). She serves on the board of advisors for the National Cancer Institute, on 12 external advisory boards for NCI-designated cancer centers and on Exai Bio.

She is an active member of several committees with the American Society for Clinical Oncology (ASCO), in addition to serving on other academic and for-profit advisory boards.